Physician profile
Ibrahim Nc Oudeh
NPI 1538240437
$10,752.19
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,523 · 2020: $1,112 · 2021: $3,454 · 2022: $2,414 · 2023: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $248.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,547.74 | 2019-2022 | |
| Amgen INC. | $1,179.20 | 2019-2022 | |
| Novo Nordisk INC | $1,174.39 | 2019-2023 | Wegovy |
| Beckman Coulter, INC. | $1,119.79 | 2022 | |
| Avanir Pharmaceuticals, INC. | $1,087.97 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $777.35 | 2021-2023 | |
| Esperion Therapeutics, INC. | $539.83 | 2020-2021 | |
| Abbvie INC. | $472.92 | 2021 | |
| Lilly USA, LLC | $451.11 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $446.21 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $271.53 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.79 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $238.11 | 2021 | |
| Novartis Pharmaceuticals Corporation | $212.83 | 2019-2020 | |
| Allergan, INC. | $189.54 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $133.87 | 2019 | |
| Gilead Sciences, INC. | $124.99 | 2019 | |
| Galderma Laboratories, L.P. | $124.96 | 2020 | |
| Sunovion Pharmaceuticals INC. | $117.95 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.01 | 2019 | |
| Sanofi-Aventis U.S. LLC | $49.47 | 2019 | |
| Glaxosmithkline, LLC. | $39.81 | 2020-2021 | |
| Forte Bio-Pharma LLC | $33.68 | 2019 | |
| Zealand Pharma US, INC. | $24.61 | 2020-2021 | |
| Mannkind Corporation | $13.84 | 2019 | |
| Assertio Therapeutics, INC. | $13.83 | 2019 | |
| Hikma Pharmaceuticals USA | $11.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ibrahim Oudeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.